CRISPR Therapeutics AG · NASDAQ:CRSP

CRISPR Therapeutics — Investor Presentation (March 2024)

28 slides from CRISPR Therapeutics's investor presentation, March 2024

  1. Slide 1: Creating transformative gene-based medicines for serious diseases

    Creating transformative gene-based medicines for serious diseases Corporate Overview Q1 2024 © 2024 CRISPR Therapeutics | 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements The presentation and other related materials may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics’ expectations about any or all of th

  3. Slide 3: CRISPR Therapeutics Highlights

    CRISPR Therapeutics Highlights Leading gene editing company with a strong and diversified pipeline, efficient operating model, and proven track record of execution Best-in-class technology, strategy, and execution culminating Hemoglobinopathies in the historic approval of CASGEVY Advancing multiple

  4. Slide 4: Broad and Diversified Pipeline

    Broad and Diversified Pipeline Program Disease Research IND-enabling Clinical Approved Partner Structure Severe sickle cell disease (SCD) CASGEVY1 Collaboration Transfusion-dependent β-thalassemia (TDT) Heme Next-generation conditioning Various Wholly owned2 In vivo editing of HSCs Various Wholly ow

  5. Slide 5: CASGEVY: Historic First Approval of a CRISPR-Based Medicine

    CASGEVY: Historic First Approval of a CRISPR-Based Medicine Unparalleled speed and execution Well-positioned for commercial success to a landmark approval1 Strong commercial partner with Vertex Additional regulatory milestones upcoming Significant in 2024 Robust support market ex-U.S., from the U.S.

  6. Slide 6: Groundbreaking Data Across >95 Patients

    Groundbreaking Data Across >95 Patients TDT: Transfusion independence achieved out to 45 months SCD: VOC-free and no in-patient hospitalizations for VOCs achieved out to 45.5 months Exa-cel treatment resulted in early and sustained increases in Hb and HbF leading to transfusion independence (TI12) i

  7. Slide 7: Exa-cel has a Large Addressable Market

    Exa-cel has a Large Addressable Market Opportunity to broaden market via innovation in conditioning and delivery β-thalassemia Sickle Cell Disease Exa-cel addressable market with 5,000 standard of care conditioning 30,000 Exa-cel potential market with 16,000 targeted conditioning 150,000 Potential m

  8. Slide 8: Targeted conditioning: Expanding the Number of Patients Who Can Benefit

    Expanding the Number of Patients Who Can Benefit Our approach: Antibody-drug conjugate (ADC) targeting cKit High on-target potency Targeted conditioning Proprietary GMP monoclonal antibody Optimal attributes with short half-life targeting cKit Low off-target & systemic toxicity (CD117) TOXIN s s TOX

  9. Slide 9: Three Additional Franchises Supported by World-Class Platform

    Three Additional Franchises Supported by World-Class Platform I/O and Autoimmune In Vivo Type 1 Diabetes World’s most Established First-in-class edited sophisticated CAR T mRNA-LNP beta cell therapies cell candidates, platform for for T1D, now manufactured liver editing wholly owned internally Multi

  10. Slide 10: Our Gene-Edited Allogeneic CAR T Franchise

    Our Gene-Edited Allogeneic CAR T Franchise Advancing the most sophisticated CAR T cell candidates in the clinic against multiple opportunities across heme and solid cancers, plus autoimmune indications Additional indications and targets Advancing potency-edited candidates in new areas, e.g., Next-ge

  11. Slide 11: CTX112 and CTX131 Incorporate Novel Potency Edits

    CTX112 and CTX131 Incorporate Novel Potency Edits Next-generation CRISPR gene-edited allogeneic CAR T chassis: TGFBR2 CAR disruption TCR MHC I disruption • MHC I KO: Improve disruption • TCR KO: Prevent GvHD persistence in the • Regnase-1 KO: Increase allogeneic setting and functional persistence, a

  12. Slide 12: Regnase-1 and TGFBR2 Knock-Outs Work Synergistically

    Regnase-1 and TGFBR2 Knock-Outs Work Synergistically CAR-T Cell  No TGF-β mediated Tumor microenvironment inhibition Increase in mRNAs that Regnase-1 targets  Increased proliferation  Broad cytokine secretion  Increased cytotoxicity  Repeat response to antigen challenge © 2024 CRISPR Therapeuti

  13. Slide 13: CTX112: Regnase-1/TGFBR2 KO Enhances Potency

    CTX112: Regnase-1/TGFBR2 KO Enhances Potency Potency edits in CTX112 lead to extended survival in Nalm6-Luc mice 100 CTX112: TGFBR2 KO + Regnase-1 KO 80 Regnase-1 KO TGFBR2 KO Survival (%) 60 CTX110 40 Untreated 20 N=15 mice per treated group N=5 mice for untreated group 0 0 20 40 60 80 100 Study da

  14. Slide 14: CTX131 Eliminates Three Successive Tumor Models In Vivo

    CTX131 Eliminates Three Successive Tumor Models In Vivo CTX131 eliminates three different xenograft tumor models in succession without exhaustion Tumor 1: NCI-H1975 (Lung) Tumor 2: Rechallenge 1 with ACHN (RCC) Tumor 3: Rechallenge 2 with Caki-1 (RCC) No treatment CTX131: CTX130 + Regnase-1 KO + TGF

  15. Slide 15: CTX112 Builds Upon CTX110 in B Cell Malignancies

    CTX112 Builds Upon CTX110 in B Cell Malignancies Estimated durable CR rate in R/R LBCL (ITT basis) Next-generation: CTX112 YESCARTA1 Preliminary clinical data 35% suggest improvement on the first-generation clinical profile, including significantly higher EPKINLY2 / CAR T cell expansion and 30% COLU

  16. Slide 16: Expanding CTX112 into Autoimmune Disease

    Expanding CTX112 into Autoimmune Disease CTX112 has a significant opportunity in autoimmune diseases B cell depletion following CTX110 infusion among patients with detectable B cells at baseline (N=9)  Allogeneic CAR T cells produce deep B cell depletion 1000 in B cell malignancies, as observed wit

  17. Slide 17: CTX112 and CTX131 Clinical Trials

    CTX112 and CTX131 Clinical Trials Phase 1/2 safety and efficacy Phase 1/2 safety and efficacy study evaluating CTX112 study evaluating CTX131  Relapsed or refractory B-cell  Relapsed or refractory solid tumors malignancies starting with renal cell carcinoma (RCC) Indications  Expanding into autoi

  18. Slide 18: Expanding I/O Platform to Address New Targets: GPC3

    Expanding I/O Platform to Address New Targets: GPC3 Validation building for potency-enhanced Advancing autologous, gene-edited CAR T targeting glypican-3 (GPC3) GPC3-targeted CAR T program  GPC3: Highly expressed in hepatocellular  Includes TGFβRII KO, which outperforms carcinoma (HCC) with limite

  19. Slide 19: Owning Manufacturing Gives Us Flexibility

    Owning Manufacturing Gives Us Flexibility Manufacturing CTX112 and CTX131 at our internal GMP facility These candidates exhibit increased manufacturing robustness, with a higher and more consistent number of CAR T cells produced per batch Potential for significantly lower COGS and greater scalabilit

  20. Slide 20: Applying Plug-and-Play In Vivo Platform Across Multiple Diseases

    Applying Plug-and-Play In Vivo Platform Across Multiple Diseases Established plug-and-play LNP/ Advancing broad portfolio of Potential to transform the mRNA platform for in vivo gene wholly-owned in vivo programs treatment paradigm for CVD disruption, starting in the liver across rare and common dis

  21. Slide 21: CTX310 and CTX320 Could Transform the Treatment Paradigm for ASCVD

    CTX310 and CTX320 Could Transform the Treatment Paradigm for ASCVD The chronic care model A new treatment paradigm: one-time Daily Weekly Multiple infusions Surgical CRISPR-based therapies with the potential to… medications injections annually interventions  Recapitulate the proven benefit of targe

  22. Slide 22: CTX310 and CTX320: A One-Time Dose to Treat CVD

    CTX310 and CTX320: A One-Time Dose to Treat CVD Intravenous delivery Reduced atherogenic CRISPR/Cas9-based editing targeting the liver lipoprotein concentrations CTX310 or CTX320 Endothelial lipase LDL-C ANGPTL3 Endocytosis and TG (CTX310) Lipoprotein lipase Endosomal escape Lp(a) DNA cleavage (CTX3

  23. Slide 23: CTX310 Targeting ANGPTL3 for Cardiovascular Disease

    CTX310 Targeting ANGPTL3 for Cardiovascular Disease Natural loss-of-function mutations in ANGPTL3 are associated A one-time, CRISPR-based therapy could recapitulate the with reduced LDL-C, triglycerides (TG), and ASCVD risk protective effect of naturally occurring loss-of-function without any negati

  24. Slide 24: CTX320 Targeting Lp(a), an Independent Risk Factor for ASCVD

    CTX320 Targeting Lp(a), an Independent Risk Factor for ASCVD Elevated lipoprotein(a) [Lp(a)] levels Up to 20% of the global population A one-time, CRISPR-based therapy increase ASCVD risk, as observed has elevated Lp(a)6,7, primarily could recapitulate the protective across numerous studies1,2,3,4,5

  25. Slide 25: Three Parallel Efforts in Type 1 Diabetes (T1D)

    Three Parallel Efforts in Type 1 Diabetes (T1D) Gene editing is key to achieving the goal of developing a beta-cell replacement product to treat diabetes without requiring long-term immunosuppression 1 2 3 CTX211 (formerly VCTX211) Deviceless approach Non-exclusive license with Vertex First-in-class

  26. Slide 26: Next-Generation Editing: Poised to Continue Our Leading Role

    Next-Generation Editing: Poised to Continue Our Leading Role The race to bring next-generation Both editing and delivery expertise No one editing approach will gene-editing technologies to the needed to make the required edit dominate – each disease will clinic has just begun in the required locatio

  27. Slide 27: Strong U.S. and Global Foundational IP Position

    Strong U.S. and Global Foundational IP Position United States Europe and Global CVC granted patents of broad scope; CVC granted foundational patents, multiple applications progressing including use in eukaryotes Patents of broad scope granted in the EU, Canada, China, 55 Patents of broad scope grant

  28. Slide 28: Several Upcoming Catalysts in the Next Months

    Several Upcoming Catalysts in the Next 12 months Heme Program Disease Status CASGEVY SCD and TDT EMA approval decision; TDT PDUFA date March 30, 2024 B-cell malignancies Trial ongoing – data update in 2024 I/O & Autoimmune CTX112 SLE Trial to be initiated 1H 2024 Solid tumors Trial in RCC ongoing –

CRISPR Therapeutics — Investor Presentation (March 2024) on 6ix